Trials / Recruiting
RecruitingNCT06598787
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Recurrent Glioblastoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 for Injection | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-09-19
- Last updated
- 2025-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06598787. Inclusion in this directory is not an endorsement.